MPN Advances Day 2017 | MPNs and thrombosis: reducing the risk
Patients with myeloproliferative neoplasm (MPNs) are at a higher risk of mortality due to thrombosis compared with unaffected individuals. Speaking from the Myeloproliferative Neoplasms Advances Day 2017 in London, UK, Tiziano Barbui, MD, from Hospital Papa Giovanni XXIII, Bergamo, Italy, discusses this issue and highlights the efforts being made to combat it, including cytoreductive therapy and anticoagulants. Prof. Barbui then provides an overview of his group’s exciting ongoing studies, which are collecting data from over 1,000 MPN patients.
Get great new content delivered to your inboxSign up